Research updates in kidney cancer
Burned in the USA — the high risk of burnout for US oncologists
Body and mind combined in cancer care
Choosing the right treatment pathway in pancreatic cancer
Oncology community standing together, apart
Advances in lung cancer
Breast cancer care in the Covid context
Chemotherapy and Covid-19 — assessing the outcomes
Clinical perspectives on melanoma
ASCO Annual Meeting 2019, Chicago, IL
Research updates in kidney cancer
November 23, 2020
Burned in the USA — the high risk of burnout for US oncologists
November 23, 2020
Body and mind combined in cancer care
November 23, 2020
Choosing the right treatment pathway in pancreatic cancer
November 23, 2020
Oncology community standing together, apart
November 23, 2020
Advances in lung cancer
November 23, 2020
Breast cancer care in the Covid context
November 23, 2020
Chemotherapy and Covid-19 — assessing the outcomes
November 23, 2020
Clinical perspectives on melanoma
November 23, 2020
ASCO Annual Meeting 2019, Chicago, IL
July 3, 2019
ISMO Travel Bursary Awards 2021
The ISMO meeting featured some of the best cancer research currently being undertaken in Ireland This year’s Irish Society of Medical Oncology (ISMO) annual meeting took place on Friday, 29 January 2021. As a result of Covid-19, the meeting was held virtually, streaming live from the Fintan Gunne Theatre, Catherine McAuley Centre, Mater Misericordiae University…
CPD Module- Cervical cancer
2 CPD Hours Authors Caitriona Duggan, Registered Advanced Nurse Practitioner, Oncology Department, Portiuncula Hospital, Ballinasloe, Co. Galway. This module outlines what ‘cervical’ is. It highlights the epidemiology, pathogenesis and risk factors of cervical cancer. The module summarises the staging and complex management options of the various stages that comprise cervical cancer. It also discusses cervical…
CPD Module- Multiple myeloma
1.5 CPD Hours Authors Ronan Desmond MD, MRCPI, FRCPath, Consultant Haematologist, Tallaght Hospital, Dublin 24 and Naas General Hospital, Co Kildare This module will begin with a case study and discuss further when to suspect the presence of myeloma and investigations to consider. I will also discuss indications to treat and the current treatment paradigm…
PARP inhibitors in cancer – shifting the paradigm to frontline treatment
The last decade has seen major advances in oncology therapy with the addition of PARP inhibitors, with significant updated data on their usage across a range of cancers in the last 12 months Tubo-ovarian cancer The last 12 months has continued to see PARP inhibitors lead the field as regards therapeutic advancement in advanced tubo-ovarian…
2019 European Society for Medical Oncology (ESMO) Asia Congress
First China-manufactured trastuzumab biosimilar HLX02 global phase 3 trial met primary endpoint in breast cancer outcomes The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase 3 study reported at…
Related Sites
